Citurgia Biochemicals Ltd (506373)
Latest quarterly results (Q4 FY26)
In its latest reported quarter, Q4 FY26, Citurgia Biochemicals' revenue was ₹0.0 Cr, and net profit ₹-0.3 Cr (a bigger loss than a year earlier).
| Q4 FY26 (₹ Cr) | Value | YoY vs Q4 FY25 | QoQ |
|---|---|---|---|
| Revenue | ₹0.0 | — | — |
| Operating profit | ₹-0.2 | loss widened | loss narrowed |
| Net profit | ₹-0.3 | loss widened | loss narrowed |
| EPS (₹) | -0.02 | loss widened | — |
📢 Recent Corporate Announcements
Citurgia Biochemicals continues to report zero operational revenue for the quarter ended June 30, 2026, maintaining a trend of operational dormancy. The company recorded a net loss of Rs 8.20 lakhs, which is a marginal improvement from the Rs 8.39 lakh loss in the same quarter last year and a significant reduction from the Rs 25.82 lakh loss in the preceding quarter. Expenses were primarily driven by depreciation (Rs 5.15 lakhs) and employee benefits (Rs 3.00 lakhs). With a negative net worth of Rs 8 crore and zero TTM revenue, the company's financial position remains extremely weak.
- Total Income from operations remained at Rs 0.00 for the quarter ended June 30, 2026.
- Net loss for the quarter stood at Rs 8.20 lakhs, compared to a loss of Rs 25.82 lakhs in the preceding quarter (March 2026).
- Total expenses decreased to Rs 8.20 lakhs from Rs 25.82 lakhs in the previous quarter, largely due to lower 'Other Expenses'.
- Employee benefit expenses remained constant at Rs 3.00 lakhs compared to the corresponding quarter of the previous year.
- Depreciation and amortization expenses accounted for the largest portion of the loss at Rs 5.15 lakhs.
Citurgia Biochemicals has scheduled a board meeting for August 12, 2026, to consider and approve unaudited standalone financial results for the quarter ended June 30, 2026. The company is currently in a distressed financial state, reporting zero revenue for the last four consecutive quarters and the full FY26. With a negative net worth of Rs 8 Cr and debt of Rs 7 Cr, the company's operational status remains a critical concern for stakeholders. Additionally, the promoter holding is exceptionally high at 99.36%, resulting in extremely low liquidity for retail investors.
- Board meeting scheduled for August 12, 2026, to approve Q1 FY27 results
- Company reported Rs 0 Cr revenue for the entire FY26 period
- Net worth remains negative at Rs -8 Cr as per latest financial context
- Promoter holding is stagnant at a very high 99.36%
- Trading window has been closed since July 1, 2026, for designated persons
Citurgia Biochemicals has announced the resignation of CS Yatendra Kumar from the position of Company Secretary and Compliance Officer, effective July 24, 2026. The resignation is attributed to the individual pursuing career opportunities outside the company. This administrative change occurs in a company that is currently non-operational, reporting zero revenue for the last four quarters and a negative net worth of Rs -8 Cr. The board will formally consider the resignation in its next meeting.
- CS Yatendra Kumar (ACS-27994) resigned effective from the closing of business hours on July 24, 2026
- The company reported Rs 0.0 Cr revenue for the quarter ended March 2026
- Net worth of the company stands at Rs -8 Cr as per latest available data
- Promoter holding remains exceptionally high at 99.36% as of June 2026
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
